STIM
HEALTHCARENeuronetics Inc
$1.91-0.26 (-11.98%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving STIM Today?
No stock-specific AI insight has been generated for STIM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.80$4.85
$1.91
Fundamentals
Market Cap$128M
P/E Ratio—
EPS$-0.54
Dividend Yield—
Dividend / Share—
ROE-1.3%
Profit Margin-0.2%
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding69.6M
STIM News
21 articles- Neuronetics Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Neuronetics, Inc. Q1 2026 Earnings Call SummaryMoby·May 5, 2026
- Neuronetics (STIM) Q1 2026 Earnings TranscriptMotley Fool·May 5, 2026
- Neuronetics (STIM) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 5, 2026
- Neuronetics Reports First Quarter 2026 Financial and Operating ResultsYahoo Finance·May 5, 2026
- How The Neuronetics (STIM) Investment Story Is Evolving With A Reset Price TargetYahoo Finance·May 2, 2026
- Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 29, 2026
- Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference CallYahoo Finance·Apr 21, 2026
- How The Neuronetics (STIM) Investment Story Is Reset As Analysts Rework Valuation AssumptionsYahoo Finance·Apr 18, 2026
- Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse PractitionersYahoo Finance·Apr 13, 2026
- Deal Dispatch: Unilever Buys Grüns, Pershing Square Eyes Universal Music Group, Saks Global Reorganization PlanBenzinga·Apr 10, 2026
- Neuronetics Comments on Letter from Pointillist Family OfficeYahoo Finance·Apr 7, 2026
- Neuronetics Announces Chief Financial Officer TransitionYahoo Finance·Apr 6, 2026
- Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS BusinessYahoo Finance·Apr 6, 2026
- How The Neuronetics (STIM) Story Is Shifting As Analysts Rework Valuation AssumptionsYahoo Finance·Apr 3, 2026
- Neuronetics, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 17, 2026
- Neuronetics (STIM) Q4 2025 Earnings TranscriptMotley Fool·Mar 17, 2026
- Neuronetics Q4 Earnings Call HighlightsMarketbeat·Mar 17, 2026
- Neuronetics: Q4 Earnings SnapshotYahoo Finance·Mar 17, 2026
- Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsYahoo Finance·Mar 17, 2026
- Neuronetics Appoints Dan Reuvers as President and Chief Executive OfficerYahoo Finance·Mar 17, 2026
All 21 articles loaded
Price Data
Open$2.16
Previous Close$2.17
Day High$2.19
Day Low$1.88
52 Week High$4.85
52 Week Low$0.80
52-Week Range
$0.80$4.85
$1.91
Fundamentals
Market Cap$128M
P/E Ratio—
EPS$-0.54
Dividend Yield—
Dividend / Share—
ROE-1.3%
Profit Margin-0.2%
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding69.6M
About Neuronetics Inc
Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—